Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2010 | 5 | 1 | 36-40

Article title

Plasma level of myeloperoxidase in children with juvenile idiopathic arthritis (a pilot study)


Title variants

Languages of publication



To examine the plasma levels of MPO in oligoarthritis and polyarthritis subtypes of JIA in comparison with healthy age-matched controls. Thirty-eight JIA patients (25 girls and 13 boys) aged 9.1–11.8 years and 23 healthy controls (8 girls and 15 boys) participated in the study. Twenty-one patients had oligoarthritis (8 with extended oligoarthritis) and 17 had polyarthritis (among them three were seropositive). The plasma concentration of MPO was measured by the ELISA technique (OxisResearchTM, BIOXYTECH® MPO-EIATM, Portland, OR USA). The mean plasma concentration of MPO in the JIA group was significantly higher than in the control group (76.6±24.8 µg/L versus 62.7±15.6 µg/L; p=0.01). Patients with polyarthritis presented a significantly higher mean plasma MPO level than patients with oligoarthritis (81.3±25.6 µg/L and 62.1±27.1 µg/L, respectively; p=0.02). Different subtypes of JIA may have different MPO-related backgrounds. MPO is a new potent inflammatory marker. Patients with polyarthritis have higher mean plasma MPO levels than patients with oligoarthritis and may therefore have an enhanced risk for subclinical oxidative stress-related atherogenic promotion.










Physical description


1 - 2 - 2010
29 - 1 - 2010


  • Department of Pediatrics, Tartu University, Lunini 6, Tartu, 51014, Estonia
  • Department of Pediatrics, Tartu University, Lunini 6, Tartu, 51014, Estonia
  • Department of Biochemistry, Tartu University, Ravila 19, Tartu, 50411, Estonia
  • Tallinn Children’s Hospital, Tervise 28, Tallinn, 13419, Estonia
  • Children’s Clinic, Tartu University Hospital, Lunini 6, Tartu, 51014, Estonia
  • Department of Pediatrics, Tartu University, Lunini 6, Tartu, 51014, Estonia
  • Department of Biochemistry, Tartu University, Ravila 19, Tartu, 50411, Estonia
  • Department of Pediatrics, Tartu University, Lunini 6, Tartu, 51014, Estonia


  • [1] Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995; 22:1566–1569
  • [2] Faith M, Sukumaran A, Pulimood AB, Jacob M. How reliable an indicator of inflammation is myeloperoxidase activity? Clin Chim Acta 2008; 396:23–25 http://dx.doi.org/10.1016/j.cca.2008.06.016[Crossref][WoS]
  • [3] Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: A new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm 2008; 2008:135625 http://dx.doi.org/10.1155/2008/135625[WoS][Crossref]
  • [4] Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77:598–625 http://dx.doi.org/10.1189/jlb.1204697[Crossref]
  • [5] Ramos VA, Ramos PA, Dominguez MC. Role of oxidative stress in the maintenance of inflammation in patients with juvenile rheumatoid arthritis. J Pediatr 2000; 76:125–132
  • [6] Kampus P, Kals J, Ristimäe T, Muda P, Ulst K, Zilmer K, Salonen RM, Tuomainen TP, Teesalu R, Zilmer M. Augmentation index and carotid intima-media thickness are differently related to age, C-reactive protein and xidized low-density lipoprotein. J Hypertens 2007; 25:819–825 http://dx.doi.org/10.1097/HJH.0b013e328014952b[WoS][Crossref]
  • [7] Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, Belaaouaj A, Heinecke JW. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest 2002; 109:1287–1289
  • [8] Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 2000; 28:1717–1725 http://dx.doi.org/10.1016/S0891-5849(00)00229-X[Crossref]
  • [9] Minohara M, Matsuoka T, Li W, Osoegawa M, Ishizu T, Ohyagi Y, Kira J. Upregulation of myeloperoxidase in patients with opticospinal multiple sclerosis: positive correlation with disease severity. J Neuroimmunol 2006; 178:156–160 http://dx.doi.org/10.1016/j.jneuroim.2006.05.026[Crossref]
  • [10] Lefkowitz DL, Lefkowitz SS. Microglia and myeloperoxidase: A deadly partnership in neurodegenerative disease. Free Radic Biol Med 2008; 45:726–731 http://dx.doi.org/10.1016/j.freeradbiomed.2008.05.021[Crossref]
  • [11] Lotito AP, Muscará MN, Kiss MH, Teixeira SA, Novaes GS, Laurindo IM, Silva Ca, Mello SB. Nitric oxide-derived species in synovial fluid from patients with juvenile idiopathic arthritis. J Rheumatol 2004; 31:992–997
  • [12] Liskmann S, Zilmer M, Vihalemm T, Salum O, Fischer K. Correlation of peri-implant health and myeloperoxidase levels: a cross-sectional clinical study. Clin Oral Implants Res 2004; 15:546–552 http://dx.doi.org/10.1111/j.1600-0501.2004.01061.x[Crossref]
  • [13] Renke J, Szlagatys A, Hansdorfer-Korzon R, Szumera M, Kamińska B, Knap N, Popadiuk S, Szarszewski A, Woźniak M. Persistence of protein oxidation products and plasma antioxidants in juvenile idiopathic arthritis. A one-year follow-up study. Clin Exp Rheumatol 2007; 25:112–114
  • [14] Bonomini F, Tengattini S, Fabiano A, Bianchi R, Rezzani R. Atherosclerosis and oxidative stress. Histol Histopathol 2008; 23:381–390
  • [15] Düzgünçinar O, Yavuz B, Hazirolan T, Deniz A, Tokgözoğlu SL, Akata D, Demirpençe E. Plasma myeloperoxidase is related to the severity of coronary artery disease. Acta Cardiol 2008; 63:147–152 http://dx.doi.org/10.2143/AC.63.2.2029520[Crossref][WoS]
  • [16] Rutgers A, Heeringa P, Giesen JE, Theunissen RT, Jacobs H, Tervaert JW. Neutrophil myeloperoxidase activity and the influence of two single-nucleotide promoter polymorphisms. Br J Haematol 2003; 123:536–538 http://dx.doi.org/10.1046/j.1365-2141.2003.04602.x[Crossref]
  • [17] Doi K, Noiri E, Maeda R, Nakao A, Kobayashi S, Tokunaga K, Fujita T. Functional polymorphism of the myeloperoxidase gene in hypertensive nephrosclerosis dialysis patients. Hypertens Res 2007; 30:1193–1198 http://dx.doi.org/10.1291/hypres.30.1193[Crossref][WoS]
  • [18] Hoi A, Leininger-Muller B, Poirier O, Siest G, Gautier M, Elbaz A, Amarenco P, Visvikis S. Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome. Atherosclerosis 2003; 167:223–230 http://dx.doi.org/10.1016/S0021-9150(02)00041-2[Crossref]
  • [19] Reynolds WF, Sermet-Gaudelus I, Gausson V, Feuillet MN, Bonnefont JP, Lenoir G, Descamps-Latscha B, Witko-Sarsat V. Myeloperoxidase promoter polymorphism −463G is associated with more severe clinical expression of cystic fibrosis pulmonary disease. Mediators Inflamm 2006; 2:36735

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.